Investing.com - Decibel Therapeutics (NASDAQ: DBTX) reported fourth quarter EPS of $-0.640, $0.24 worse than the analyst estimate of $-0.400. Revenue for the quarter came in at $10M versus the consensus estimate of $7.5M.
Decibel Therapeutics's stock price closed at $4.080. It is up 88.020% in the last 3 months and up 40.690% in the last 12 months.
Decibel Therapeutics saw 1 positive EPS revisions and 4 negative EPS revisions in the last 90 days. See Decibel Therapeutics's stock price’s past reactions to earnings here.
According to InvestingPro, Decibel Therapeutics's Financial Health score is "weak performance".
Check out Decibel Therapeutics's recent earnings performance, and Decibel Therapeutics's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar